help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kineman, R. D.
Right arrow Articles by Frohman, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kineman, R. D.
Right arrow Articles by Frohman, L. A.
Endocrinology Vol. 142, No. 9 3764-3773
Copyright © 2001 by The Endocrine Society


ARTICLES

The Effect of GHRH on Somatotrope Hyperplasia and Tumor Formation in the Presence and Absence of GH Signaling

R. D. Kineman, L. T. Teixeira, G. V. Amargo, K. T. Coschigano, J. J. Kopchick and L. A. Frohman

Department of Medicine, University of Illinois (R.D.K., L.T.T., G.V.A., L.A.F.), Chicago, Illinois 60612; and Edison Biotechnology Institute (K.T.C., J.J.K.) and Department of Biochemical Sciences, College of Osteopathic Medicine, Ohio University, Athens, Ohio 45701

Address all correspondence and requests for reprints to: Rhonda D. Kineman, Ph.D., Department of Medicine (M/C 640), University of Illinois, 1819 West Polk, Chicago, Illinois 60612.

Excessive GHRH stimulation leads to somatotrope hyperplasia and, ultimately, pituitary adenoma formation in the metallothionein promoter-driven human GHRH (hGHRH) transgenic mouse. This pituitary phenotype is similar to that observed in humans with ectopic production of GHRH. In both mice and man, GHRH hyperstimulation also results in dramatic increases in circulating GH and IGF-I. To determine whether GH/IGF-I modulates the development and growth rate of GHRH-induced pituitary tumors, pituitary growth and histology were evaluated in mice generated from cross-breeding metallothionein promoter-driven hGHRH transgenic mice with GH receptor binding protein (GHR) gene disrupted mice (GHR-/-). Expression of the hGHRH transgene in 2-month-old GHR intact (GHR+) mice resulted in the doubling of pituitary weight that was largely attributed to an increase in the number of GH-immunopositive cells. Pituitary weight of GHR+ hGHRH mice did not significantly change between 2 and 6 months of age, whereas at 12 months, weights increased up to 100-fold those of GHR+ pituitaries, and 70% of the glands contained grossly visible adenomas. All adenomas stained positively for GH, whereas some showed scattered PRL staining. Pituitaries of GHR-/- mice were half the size of those of GHR+ mice. Although reduced in size, the histological features of GHR-/- mouse pituitaries were suggestive of somatotrope hyperplasia. Despite evidence of somatotrope hyperplasia, pituitaries from GHR-/- mice as old as 28 months of age were similar in size to those of 2-month-old mice and did not show signs of adenoma formation. Expression of the hGHRH transgene in GHR-/- mice did not significantly increase pituitary size between 2 and 6 months of age. However, at 12 months the majority of GHR-/-, hGHRH pituitaries developed adenomas with mean pituitary weight and histological features similar to those of GHR+, hGHRH mice. These observations demonstrate that intact GH signaling is not required for GHRH tumor formation. Although the majority of GHR+, hGHRH and GHR-/-, hGHRH pituitaries developed tumors by 12 months of age, a small subset remained morphologically indistinct from those at 2 months of age. These observations taken together with the fact that overt tumor formation is preceded by a static pituitary growth phase between 2 and 6 months, indicates that protective mechanisms are in place to maintain pituitary mass despite hGHRH hyperstimulation.




This article has been cited by other articles:


Home page
EndocrinologyHome page
R. M. Luque, G. Amargo, S. Ishii, C. Lobe, R. Franks, H. Kiyokawa, and R. D. Kineman
Reporter Expression, Induced by a Growth Hormone Promoter-Driven Cre Recombinase (rGHp-Cre) Transgene, Questions the Developmental Relationship between Somatotropes and Lactotropes in the Adult Mouse Pituitary Gland
Endocrinology, May 1, 2007; 148(5): 1946 - 1953.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. S. Khan, M. L. Fiorotto, K. K. Cummings, M. A. Pope, P. A. Brown, and R. Draghia-Akli
Maternal GHRH plasmid administration changes pituitary cell lineage and improves progeny growth of pigs
Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E224 - E231.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. S. Khan, M. L. Fiorotto, L.-A. Hill, P. B. Malone, K. K. Cummings, D. Parghi, R. J. Schwartz, R. G. Smith, and R. Draghia-Akli
Nonhereditary Enhancement of Progeny Growth
Endocrinology, September 1, 2002; 143(9): 3561 - 3567.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society